 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | LICL.XH2O |
| Molecular Weight | 42.39 (anhydrous basis) |
| Exact Mass | 59.995 |
| CAS # | 85144-11-2 |
| PubChem CID | 23681138 |
| Appearance | White to off-white solid powder |
| Density | 1.21 g/mL at 20 °C |
| Boiling Point | 1382 °C |
| Melting Point | 605 °C(lit.) |
| Flash Point | -4 °F |
| Index of Refraction | n20/D 1.381 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Heavy Atom Count | 3 |
| Complexity | 2 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | VXJIMUZIBHBWBV-UHFFFAOYSA-M |
| InChi Code | InChI=1S/ClH.Li.H2O/h1H;;1H2/q;+1;/p-1 |
| Chemical Name | lithium;chloride;hydrate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | GSK-3β |
| ln Vitro | In IBV Beaudette-infected BHK cells, lithium chloride hydrate (5 and 20 mM, 36 hours) reduces cytopathic effects and IBV replication [1]. IBV-induced apoptosis and inflammation in BHK cells are inhibited by lithium chloride hydrate (5 and 20 mM, 36 hours) [1]. The efficiency of neurospheres produced from induced pluripotent stem cells is increased by lithium chloride hydrate (1 mg/mL) [4]. PC12 cells are shielded against apoptosis caused by morphine (HY-P1701) by lithium chloride hydrate (1.2 mM, 72 hours) [5]. |
| ln Vivo | Rats' sevoflurane (SEV)-induced memory impairment is ameliorated by lithium chloride hydrate (60 mg/kg, ip, twice daily) [2]. In rats undergoing extraction socket repair, lithium chloride hydrate (150 mg/kg, orally, every other day) promotes bone growth [6]. |
| Cell Assay |
RT-PCR[1] Cell Types: BHK cells Tested Concentrations: 5 and 20 mM Incubation Duration: 36 h Experimental Results: Blocked the expression of NF-κB, NLRP3, TNF-α, and IL-1β. Blocked levels of Caspase-3, Bax and increased Bcl-2 level. |
| Animal Protocol |
Animal/Disease Models: Rats[5] Doses: 150 mg/kg Route of Administration: Oral administration (po), every other day Experimental Results: Produced greater proportion of newly formed bone (NB). Lowered the rate of TRAP-stained cells. Animal/Disease Models: Sevoflurane-induced memory impairment rats[2] Doses: 60 mg/kg Route of Administration: intraperitoneal (ip)injection, twice a day. Experimental Results: diminished escape latency, increased time in the objective quadrant and raised platform crossings. Suppresses SEV-induced oxidative stress reduces and diminished SEV-induced apoptosis in the hippocampus. |
| References |
[1]. Lithium chloride inhibits infectious bronchitis virus-induced apoptosis and inflammation. Microb Pathog. 2022 Jan;162:105352. [2]. Lithium chloride ameliorates cognition dysfunction induced by sevoflurane anesthesia in rats. FEBS Open Bio. 2020 Feb;10(2):251-258. [3]. Wang Z, et alL. Baicalin Coadministration with Lithium Chloride Enhanced Neurogenesis via GSK3β Pathway in Corticosterone Induced PC-12 Cells. Biol Pharm Bull. 2022 May 1;45(5):605-613. [4]. Lithium chloride improves the efficiency of induced pluripotent stem cell-derived neurospheres. Biol Chem. 2015 Aug;396(8):923-8. [5]. Lithium chloride protects PC12 pheochromocytoma cell line from morphine-induced apoptosis. Arch Iran Med. 2008 Nov;11(6):639-48. |
Solubility Data
| Solubility (In Vitro) |
DMSO : 50 mg/mL H2O : ≥ 50 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |